SUMO: regulating the regulator by Bossis, Guillaume & Melchior, Frauke
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Cell Division
Open Access Review
SUMO: regulating the regulator
Guillaume Bossis1,2 and Frauke Melchior*2
Address: 1Institut de Génétique Moléculaire de Montpellier, CNRS, 1919 route de Mende, 34293 - Montpellier Cedex 05, France and 2Dept. of 
Biochemie I, University Goettingen, Humboldt Allee 23, 37073 Goettingen, Germany
Email: Guillaume Bossis - guillaume.bossis@igmm.cnrs.fr; Frauke Melchior* - F.Melchior@medizin.uni-goettingen.de
* Corresponding author    
Abstract
Post-translational modifiers of the SUMO (Small Ubiquitin-related Modifier) family have emerged
as key regulators of protein function and fate. While the past few years have seen an enormous
increase in knowledge on SUMO enzymes, substrates, and consequences of modification,
regulation of SUMO conjugation is far from being understood. This brief review will provide an
overview on recent advances concerning (i) the interplay between sumoylation and other post-
translational modifications at the level of individual targets and (ii) global regulation of SUMO
conjugation and deconjugation.
The many roles of sumoylation
Sumoylation, which consists in the covalent and reversi-
ble conjugation of Small Ubiquitin-related Modifiers
(SUMO-1, 2 and 3 in mammals) to target proteins, is an
essential cellular process from yeasts to mammals. In S.
cerevisiae, disruption of the SUMO pathway leads to a G2/
M cell cycle arrest [1]; In mouse, it leads to embryonic
death at early stages [2].
The number of known SUMO targets is growing exponen-
tially, and it seems likely that this modification is as com-
mon as phosphorylation to regulate biological processes
[3]. Most SUMO targets were initially found in the
nucleus, but it is now clear that sumoylation also regulates
cytoplasmic-, and even plasma membrane associated pro-
teins. Modification has been linked to pathways as diverse
as intracellular trafficking, cell cycle, DNA repair and rep-
lication, RNA metabolism and cell signalling (for detailed
description of sumoylation functions see [4]). At a molec-
ular level, sumoylation alters protein functions by mask-
ing and/or adding interaction surfaces, or by inducing
conformational changes that result in altered interactions
(for detailed examples see [5]). As a consequence, a wide
variety of downstream consequences have been observed,
including changes in localisation, enzymatic activity, or
stability.
Among the many known targets of sumoylation, a large
number are regulators of gene expression, in particular
transcription factors, co-activators or repressors. Here, the
emerging picture is that sumoylation essentially results in
down-regulation of gene expression. Albeit the molecular
mechanisms underlying this repression by SUMO are still
ill defined, they seem to involve SUMO-dependent
recruitment of transcriptional repressors such as HDACs
directly to promoters [6].
The SUMO conjugation and deconjugation 
pathway
All SUMO isoforms are conjugated via a conserved enzy-
matic cascade that resembles that of ubiquitin conjuga-
tion (Figure 1). SUMO is first activated by formation of a
thioester bond between its C-terminal glycine and the cat-
alytic cysteine of the heterodimeric E1 activating enzyme
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(Aos1/Uba2, also named SAE1/SAE2). This step requires
ATP hydrolysis. SUMO is then transferred to the catalytic
cysteine of the single E2 conjugating enzyme Ubc9. The
last step consists in the transfer of SUMO from the E2 to
the ε-amino group of a lysine side chain on the substrate,
which results in isopeptide bond formation. For this,
Ubc9 needs to recognize a specific acceptor site in the tar-
get. Many – but not all – targets contain the so-called
SUMO consensus motif, ψKxE, where Ψ is a large hydro-
phobic residue and K the acceptor lysine. The interaction
between Ubc9 and most targets is not stable enough for
efficient transfer, and therefore requires additional pro-
teins, the so-called E3 ligases. Currently known ligases
include PIAS (Protein inhibitor of activated STAT) pro-
teins, the nucleoporin RanBP2/Nup358 and the poly-
comb protein Pc2 [7,5,4].
SUMO-target conjugates are susceptible to cleavage by
specific cysteine proteases (SUMO isopeptidases) [7]. In
yeast, two isopeptidases, Ulp1 and Ulp2, are responsible
for SUMO deconjugation. Homologs of the Ulp family
were identified by sequence homology and referred to as
SENP proteins (1 to 8). SUMO isopeptidase activity was
confirmed for SENP-1 [8], SENP-2 [9-11], SENP-3
The SUMO pathway Figure 1
The SUMO pathway. All SUMO isoforms are synthetized as a precursor, containing a C-terminal extension, which is 
cleaved by specific hydrolases. Mature SUMO is then activated by formation of a thioester bond between its C-terminal glycine 
and the catalytic cysteine of the Uba2 subunit from the E1 activating enzyme (Aos1/Uba2). This step requires ATP hydrolysis. 
SUMO is then tranfered to the catalytic cysteine of the E2 activating enzyme Ubc9. The last step of the conjugating cascade 
consists in the transfer of SUMO from Ubc9 to the ε-NH2 group of a lysine side chain (isopeptide bond formation). Efficient 
modification usually requires E3 ligases. SUMOylation is a reversible and highly dynamic modification due to the presence of 
specific cysteine proteases of the Ulp/Senp family that cleave the isopeptide bond.
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[12,13], SENP5 [13] and SENP6 [14]. SENP-8, however,
turned out to be a NEDD8 specific isopeptidase [15-17].
Whether other types of SUMO isopeptidases exist is still
not clear. All SENPs share a conserved catalytic domain
but have distinct N-terminal extensions, which might be
responsible for their different intracellular localisations
[7].
The interplay between modifying enzymes and isopepti-
dases is responsible, at least in part, for the late discovery
of SUMO: with rare exceptions such as RanGAP1, the first
protein for which sumoylation was shown, most SUMO
targets are modified at very low steady state levels in vivo.
Moreover, upon cell lysis most sumoylated proteins are
highly susceptible to demodification by isopeptidases.
Dynamic sumoylation/desumoylation cycles may also be
responsible for a frequently observed conundrum: while
only a small fraction of a given target is sumoylated at
steady state, their corresponding SUMOylation-deficient
mutants can have striking effects [4].
Regulation of sumoylation at the substrate level
While selected SUMO targets are modified constitutively,
many proteins are sumoylated in a temporally or spatially
Regulation of SUMOylation through target modification Figure 2
Regulation of SUMOylation through target modification. Distinct post-translational modifications of the target protein 
can affect its sumoylation. A) Competition with other lysine-directed modifications such as ubiquitinylation of acetylation abol-
ishes sumoylation. B) Phosphorylation can act both as a positive and a negative regulator of sumoylation. Enhanced sumoylation 
has been observed, e.g., when the phosphorylated residue is part of an extended SUMO acceptor site, the PDSM (Phosphoryla-
tion Dependant SUMO Motif; with the sequence motif ΨKxExxSP [30]).
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regulated fashion. Examples for target specific regulation
are mitotic modification of yeast septins [18] and topoi-
somerase II [19], PML demodification [20] in mitosis, S.
c. PCNA sumoylation in S-phase [21,22], stress induced
sumoylation of heat shock factor I [23], or circadian cycle
dependant sumoylation of BMAL1 [24]. While only frag-
mented knowledge concerning this regulation is availa-
ble, it is already clear that there are several distinct
mechanisms to enhance or inhibit sumoylation of indi-
vidual target proteins.
One obvious way to regulate sumoylation at the target
level is through target phosphorylation (Figure 2). As will
become evident from the examples below, phosphoryla-
tion may serve both as a positive and a negative signal for
sumoylation. An example for negative regulation is the
sumoylation of AP-1 transcription factors c-Jun and c-Fos,
which is reduced after phosphorylation of specific resi-
dues (Ser 63 and 73 for c-Jun and Thr 232 for c-Fos) by
JNK (in the case of c-Jun) and by an unidentified, Ras acti-
vated, kinase in the case of c-Fos [25,26]. Consistent with
the finding that sumoylation inhibits their transcriptional
activity, phosphorylation of these residues is known to
activate c-Jun and c-Fos dependent transcription. Along
the same line, phosphorylation of p53 at Ser 20, induced
by DNA damaging agents, strongly reduces its sumoyla-
tion [27]. ELK-1 phosphorylation upon activation of the
MAPK pathway was also shown to inhibit its sumoylation
[28]. Whether phosphorylation serves to recruit isopepti-
dases, blocks access of Ubc9 or E3 ligases, or prevents
modification by other mechanisms is currently unknown.
In other cases, phosphorylation can enhance sumoyla-
tion. This was first demonstrated for the Heat Shock Fac-
tor HSF1. Its phosphorylation on Ser 303, induced after
heat shock, is required for efficient sumoylation on the
nearby Lys 298 [29]. A S303E mutant is more efficiently
sumoylated than wt even in vitro, suggesting that the
underlying mechanism is enhanced recruitment of the E2
conjugating enzyme Ubc9 E3 (ligases were absent in the
assay). Whether this involves a conformational change or
whether the acidic residue contributes directly to Ubc9
association awaits further analysis. Importantly, these
findings could be generalized: The sequence motif, ΨKx-
ExxSP, which is now referred to as Phosphorylation
Dependent Sumoylation Motif (PDSM) [30], is present in
various proteins, predominantly transcriptional regula-
tors. For several of these (HSF4, GATA-1, MEF2, SNIP-1
and ERRγ) the authors demonstrated that serine phospho-
rylation in the PDSM indeed enhances their sumoylation
[30]. Phosphorylation dependent sumoylation of MEF2
family members was also reported by other groups
[31,32].
Regulated MEF2 sumoylation seems to actually involve an
added level of complexity: Zhao and coworkers [33] had
already observed that MEF2D can be sumoylated or
acetylated on the same lysine residue. A report by Shalizi
et al., [34] now brings together phosphorylation, acetyla-
tion and sumoylation of MEF2A: Calcineurin dependent
dephosphorylation of Ser 408 in MEF2A, which is located
in the PDSM, was shown to promote a switch from
sumoylation to acetylation at lysine 403. Consequently,
sumoylation of MEF2 is inhibited not only by the lack of
the phosphate in the PDSM, but also by direct competi-
tion of acetylation and sumoylation on the same lysine
residue.
The concept that sumoylation and acetylation are two
competing modifications for the same lysine residue in
some SUMO targets is actually not new – it has been first
noted for the transcription factor Sp3 [35], and was also
shown for the transcriptional co-activator p300, whose
deacetylation by SIRT1 is required for its efficient
sumoylation [36]. Whether sumoylation serves to inhibit
acetylation, whether acetylation serves to prevent
sumoylation, or whether the sumoylated, acetylated and
non-modified species serve independent functions is one
of many interesting questions that arise from these stud-
ies. One particularly interesting question is whether lysine
acetylation frequently overlaps with SUMO acceptor sites.
Lysine residues are obviously not only targets for
sumoylation and acetylation, but can, e.g., also be ubiq-
uitinylated. This brings us to another type of competing
modifications – ubiquitinylation and sumoylation (Fig-
ure 2). The first example is Iκ-Bα that can be poly-ubiquit-
inylated or mono-sumoylated on lysine 21 [37]. While
poly-ubiquitinylation and subsequent degradation by the
proteasome requires signal-induced phosphorylation of
Iκ-Bα, sumoylation takes place in the absense of phos-
phorylation. It has been suggested that SUMO serves to
protect Iκ-Bα from degradation, however only a very
small fraction of Iκ-Bα is sumoylated at steady state. More
recently, it has been shown that NEMO, the Iκ-B kinase
(IKK) regulator, is also subject to both modifications on
the same lysine [38]. Here, sumoylation/desumoylation
and ubiquitinylation may be independent, but consecu-
tive, events in the activation pathway [39]. Finally, S.c. and
Xenopus laevis PCNA were shown to be mono-ubiquiti-
nylated, poly-ubiquitinylated (K63 chains) or sumoylated
on lysine 164. Different modifications are induced by dif-
ferent cues (e.g., cell cycle position or DNA damage), and
have distinct as well as cooperative functions in DNA
repair and replication (reviewed in [40]). In conclusion,
quantitative and stable modification of a given target with
SUMO or ubiquitin would obviously prevent modifica-
tion with the other moiety, and either modifier could
hence serve as an antagonist of the other. However, fromCell Division 2006, 1:13 http://www.celldiv.com/content/1/1/13
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the currently known data it seems more likely that both
types of modifications are regulated independent of each
other and serve different roles (reviewed in [41]).
The mechanisms discussed above all involve posttransla-
tional modifications of the target protein. Similar mecha-
nisms can obviously be envisioned at the level of target
Global regulation of the conjugating machinery Figure 3
Global regulation of the conjugating machinery. A) The Gam1 protein from CELO adenovirus reduces E1 and E2 
enzyme levels [47]. The resulting global desumoylation correlates with increased transcriptional activity, which is due, at least 
in part, to desumoylation of transcription factors such as Sp3. B) H2O2 inhibits SUMO conjugation by inducing the formation of 
a disulfide bond between the catalytic cysteines of the E1 and E2 enzymes. Depending on the source and dose of H2O2 (applied 
exogenously or produced endogenously) this results in local desumoylation of specific proteins or global desumoylation [52].
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specific E3 ligases or isopeptidases. Modification of these
enzymes may well alter their ability to interact with spe-
cific target proteins. Finally, many enzymes in the SUMO
pathway have restricted intracellular localisations
(reviewed in [7]). Hence sumoylation/desumoylation of
specific targets requires targeting to those sites. This has,
e.g., been shown for SP100, whose sumoylation requires
nuclear targeting [43]. Consequently, any event that
changes target or enzyme position within the cell may
influence the extent of sumoylation for a specific target.
An intriguing example is the relocalisation of the S. cerevi-
siae E3 ligase Siz1 from the nucleus to the bud neck in
mitosis, which results in septin sumoylation [42].
Regulation of the SUMO conjugating and 
deconjugating enzymes
Another, more global, way to regulate sumoylation is by
directly targeting the basic conjugation or deconjugation
machineries (Figure 3). As in many other cases, viruses
understood this was an efficient way to regulate the
sumoylation pathway for their own sake. Some viral pro-
teins from cytomegalovirus (CMV) Herpes Simplex Virus
(HSV) or adenoviruses were shown to repress sumoyla-
tion of specific proteins [44-46], although the underlying
mechanisms were not characterized. A better-documented
case of viral protein interfering with the SUMO conjuga-
tion pathway is the Gam1 protein from the CELO adeno-
virus [47]. It was shown that expression of the Gam1
protein leads to a drastic decrease in cellular SUMO con-
jugates. This loss of sumoylated proteins correlated with
the disappearance of SUMO E1 and E2, suggesting that
Gam1 could target the conjugating enzymes to degrada-
tion. What is the benefit of targeting the SUMO pathway
for virus propagation? As previously outlined, sumoyla-
tion globally represses signal transduction and gene
expression. Therefore, by preventing sumoylation, the
CELO adenovirus may globally enhance the transcription
capacity of the cell, facilitating its own propagation. This
seems indeed to be the case, as Gam1 expression
enhanced transcriptional activity via its effect on the
SUMO pathway [47]. Gam1 can interact directly with the
SUMO E1 activating enzyme, but how this triggers its dis-
appearance is presently unknown. An attractive hypothe-
sis is the recruitment of the ubiquitinylation machinery.
The SUMO conjugation/deconjugation pathway is also
globally regulated by stresses. Various stresses, including
heat shock, osmotic and high oxidative stress (H2O2)
enhance global sumoylation both in mammals [48],
plants[49] and yeasts [50]. In mammals, the increase of
conjugates was largely observed for SUMO-2/3 but not for
SUMO-1. The apparent difference in stress response
between SUMO-1 and SUMO-2/3 may point to some
interesting difference in regulation, but could also have a
rather trivial explanation: there is a large pool of free
SUMO-2 and -3 but limited SUMO-1 under normal con-
ditions [48]. A significant increase of SUMO-2/3 conjuga-
tion has also been observed in HEK293 cells exposed to
the lipid oxidation-derived electrophile 4-hydroxynone-
nal, which is an ubiquitous product of lipid oxidation
associated with oxidative stress [51].
In the case of oxidative stress in mammalian cells, the sit-
uation is more complex than it first appeared. Indeed,
increased SUMO conjugation was observed only in condi-
tions of extreme oxidative stress (100 mM H2O2), which
does not occur under physiological or even pathophysio-
logical conditions in vivo. At more relevant concentra-
tions (1 mM and below), H2O2 has opposite effects on
SUMO conjugation, leading to almost complete loss of
SUMO-1, -2 and -3 conjugates. Mechanistically, this is due
to direct inhibition of SUMO conjugation by induction of
a reversible disulfide bridge between the catalytic
cysteines of the E1 subunit Uba2 and the E2 Ubc9. Under
those conditions, SUMO isopeptidases, which also have a
cysteine in their active site, are almost not affected [52]. As
a consequence, this shifts the equilibrium in the sumoyla-
tion-desumoylation cycle towards unconjugated species
(increased sumoylation at the unphysiological dose of
100 mM H2O2 can perhaps be explained by simultaneous
inhibition of modifying and demodifying isopeptidases
enzymes). What is the benefit for the cell to block
sumoylation in case of oxidative stress? Again, this might
help to activate transcription of genes involved in the
return to normal redox conditions. Supporting this expla-
nation, AP-1 transcription factors c-Fos and c-Jun are des-
umoylated within a few minutes after H2O2 addition to
the cells. Considering that (i) sumoylation represses their
activity [25,26] and (ii) they play a key role in the tran-
scriptional activation of numerous anti-oxidant proteins
[53], their rapid desumoylation might play a key role in
the early response to oxidative stress.
The sensitivity of SUMO pathway enzymes towards
reversible inactivation by oxidation raises the question of
whether this mechanism is also important for physiologi-
cal processes that involve redox signaling. Unlike "oxida-
tive stress" which is characterized by a macroscopic shift
in cellular redox potential, redox signaling involves revers-
ible, locally and chemically defined, oxidations of key
enzymes in signaling pathways [54,55]. This involves,
e.g., peptide growth factor induced activation of mem-
brane associated NADPH oxidases that produce H2O2.
NADPH-Oxidase complexes have been found in most cell
types. Transient accumulation of hydrogen peroxide is
known to participate in receptor signaling by, e.g., revers-
ibly oxidizing the essential cysteine residues of protein
tyrosine phosphatases and the lipid phosphatase PTEN
[55].Cell Division 2006, 1:13 http://www.celldiv.com/content/1/1/13
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Highest levels of endogenous H2O2 production are known
to occur in phagocytic cells. Their activation by endotox-
ins (such as LPS) or inflammatory mediators (such as
TNF, Interferon or Phorbol esters) is responsible for the
so-called respiratory burst, which consists in the produc-
tion of ROS by a specific NADPH oxidase complex called
Phox [54]. While it was long thought that this ROS pro-
duction was only aimed at killing the engulfed pathogen,
it is now known that these ROS also play a key role as sec-
ond messengers in AP-1 and NF-κB signaling pathways
[56]. At least in this system, or more precisely in a macro-
phage cell line activated by PMA and zymosan, endog-
enously produced H2O2  is sufficient to reversibly
inactivate a significant fraction of cytoplasmic SUMO E1
and E2 enzymes. While the global pattern of SUMO con-
jugates remains unchanged, some demodification of
unknown proteins has been observed [52]. One attractive
hypothesis is that signal induced desumoylation of spe-
cific proteins in the immediate vicinity of NADPH oxi-
dases, both in macrophages and other cell types, may
contribute to activation of signal transduction and subse-
quent cellular responses.
Conclusion
Considering the enormous number of sumoylated pro-
teins that are modified in temporally and spatially con-
trolled manner, the number of known enzymes is
surprisingly limited. Nevertheless, in vitro, these enzymes
are sufficient to modify many proteins. To account for the
high specificity observed in vivo, we therefore have to
assume the existence of many regulatory mechanisms. As
outlined in this review, we are now beginning to under-
stand how sumoylation can be regulated -mechanisms
such as phosphorylation of selected targets and enzymes,
antagonistic modifications and local inactivation by oxi-
dation appear to contribute at the level of individual tar-
gets and in some scenarios globally. Different aspects of
these and other regulatory mechanisms will undoubtedly
be the focus of many exciting contributions over the next
few years.
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